Ewing sarcoma
Clinical trials for Ewing sarcoma explained in plain language.
Never miss a new study
Get alerted when new Ewing sarcoma trials appear
Sign up with your email to follow new studies for Ewing sarcoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy targets genetic flaw in rare childhood cancers
Disease control Not yet recruitingThis study tests a new immunotherapy designed to help the immune system recognize and attack cancer cells in people with high-risk Ewing sarcoma or desmoplastic small round cell tumor (DSRCT). The treatment targets a specific genetic change found only in these cancer cells, aimin…
Matched conditions: EWING SARCOMA
Phase 1 • Sponsor: Rabi Hanna • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat sarcomas
Disease control Not yet recruitingThis early-stage trial is testing a combination of specially engineered immune cells (CAR T cells) and a vaccine for people with sarcoma that has come back or spread. The goal is to see if the treatment is safe and can help shrink tumors. About 20 participants will receive the th…
Matched conditions: EWING SARCOMA
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat sarcomas
Disease control Not yet recruitingThis trial tests a 4th-generation safety-engineered CAR T cell therapy for people with relapsed or late-stage sarcomas, including osteosarcoma and Ewing sarcoma. Participants receive a single infusion of these immune cells designed to target and attack sarcoma cells. The study ai…
Matched conditions: EWING SARCOMA
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new drug tame ewing sarcoma when others fail?
Disease control Not yet recruitingThis phase 2 trial is testing an experimental drug called LX-101 to see if it can help control Ewing sarcoma and related tumors (DSRCT and SRCS) that have come back or stopped responding to standard chemotherapy. The study enrolls adolescents and young adults (age 10 and up) who …
Matched conditions: EWING SARCOMA
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New combo therapy aims to tackle tough bone cancer
Disease control Not yet recruitingThis study looks at whether giving radiation and chemotherapy together before surgery can help control high-risk Ewing sarcoma, a type of bone cancer. Researchers will follow 55 patients to see how well the treatment works and how safe it is. The goal is to improve local tumor co…
Matched conditions: EWING SARCOMA
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to stall bone sarcoma in phase 2 trial
Disease control Not yet recruitingThis study tests whether combining two drugs, lenvatinib and everolimus, works better than everolimus alone for people with advanced bone sarcoma (osteosarcoma, Ewing sarcoma, or chondrosarcoma) that has progressed after standard treatment. About 94 adults aged 19 to 79 will be r…
Matched conditions: EWING SARCOMA
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Light therapy may shield kids with cancer from chemo mouth sores
Prevention Not yet recruitingThis study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…
Matched conditions: EWING SARCOMA
Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
New app guides young cancer survivors through life after treatment
Knowledge-focused Not yet recruitingThis study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …
Matched conditions: EWING SARCOMA
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC